Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

VTX 958

Drug Profile

VTX 958

Alternative Names: TYK2 inhibitor-Ventyx Biosciences; VTX-958

Latest Information Update: 15 Jan 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Ventyx Biosciences
  • Class Anti-inflammatories; Antipsoriatics; Antirheumatics; Small molecules
  • Mechanism of Action TYK2 kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Crohn's disease
  • Research Autoimmune disorders
  • Discontinued Plaque psoriasis; Psoriatic arthritis

Most Recent Events

  • 02 Jan 2024 Ventyx Biosciences terminates the phase-II Tranquility-PsA trial in Psoriatic arthritis in USA, Spain, Poland, Hungary, Germany, Czech Republic, Bulgaria (PO) (NCT05715125)
  • 20 Dec 2023 Ventyx Biosciences terminates a phase II-SERENITY (Serenity PsO) trial in Plaque psoriasis in USA, Canada, Poland (PO) due to business decision (NCT05655299) (EudraCT2022-002887-59)
  • 06 Nov 2023 Discontinued - Phase-II for Plaque psoriasis in Canada, Poland, USA (PO)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top